// App-Quantinova.ai

: Ptcy-ATG-CSA Vs. ATG-MMF-CSA for Gvhd Prevention for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Researchers

Presenter

  • Maria Queralt Salas

Principal Investigators

  • Abel Santos Carreira

  • Eshetu G. Atenafu

  • Arjun D. Law

  • Wilson Lam

  • Ivan Pasic

  • Carol Chen

  • Dennis Dong Hwan Kim

  • Fotios V. Michelis

  • Armin Gerbitz

  • Jeffrey H. Lipton

  • Rajat Kumar

  • Jonas Mattsson

  • Auro Viswabandya

Medical Centers

  • Allogeneic Hematopoietic Cell Transplant Program, Princess Margaret Cancer Center, Toronto, Canada

  • Princess Margaret Cancer Centre, University of Toronto, Messner Allogeneic Blood and Marrow Transplantation Program, Toronto, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

  • Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada

  • Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada

  • University Health Network, Princess Margaret Cancer Centre, Toronto, Canada

  • Hematopoietic Transplantation Unit and Hematology Department, Hospital Clínic de Barcelona, Barcelona, Spain

Locations

  • Canada

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Graft-versus-host disease

Biomarkers

  • N/A

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Mycophenolic acid

  • Cyclosporine eent

  • Hydroxyzine

  • Allopurinol

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved